On November 11, OBIGEN Pharma, along with a Taiwanese physician who participated in the Phase I clinical trial of OBI-858, were invited to present their latest study on the 760 kDa botulinum toxin OBI-858 at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Japan. The presentation, highlighting the difference between botulinum toxins with varying molecular weights and its application for treating glabellar lines, garnered significant international attention.

OBIGEN stated that the AMWC (Aesthetic & Anti-Aging Medicine World Congress) is one of the premier global events in the aesthetic medicine industry, hosting annual exhibitions across Europe, the Americas, the Middle East, and Asia. The original event in Monaco draws over ten thousand participants each year for both academic and business exchanges in aesthetic medicine. In its 22nd year by 2024, AMWC has expanded to host annual conferences in multiple dedicated locations worldwide, including Japan, a market with high potential for medical aesthetics.

This year’s AMWC Japan was held from November 10th to 11th.  Professor Chih-Hung Lee, a dermatologist from Kaohsiung Chang Gung Memorial Hospital and principal investigator in the OBI-858 Phase I trial presented with the title “An Update of Botulinum Type A Toxins for Glabella Lines: Focusing on the Differential Scientific Data Between the Molecular Weights of 760 and 900 kDa,” detailed the unique formulation and molecular structure of the 760 kDa botulinum toxin, OBI-858. Based on OBIGEN’s preclinical animal studies and Phase I clinical trial data, Professor Lee showcased the wide safety margin and the potential advantages of fast onset and long duration of OBI-858, along with the before-and-after images highlighting significant improvement in glabellar lines. This paper of the Phase I study results has been accepted by a peer-reviewed international journal, providing a new option for the global medical aesthetics market.

OBIGEN further noted that OBI-858, the 760 kDa botulinum toxin is currently in Phase II clinical trials in Taiwan. Future applications will not only focus on facial wrinkle treatments but will also explore therapeutic uses such as upper and lower limb spasticity, overactive bladder, and plantar fasciitis. OBIGEN plans to collaborate with international companies to expand into global markets, aiming to meet both aesthetic and medical needs worldwide and offer alternative therapies to improve the quality of life for patients with these conditions.